Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors

Phase 1 Completed 17 enrolled Clovis Oncology, Inc.

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacokinetic and safety profiles of two formulations of CO-1.01 in patients with Advanced Solid Tumors.

Timeline

Start: 2011-04
Primary completion: 2011-10
Completion: 2013-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	gemcitabine elaidate	Small molecule	1250 mg/m2	Intravenous

Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications